Abbott's Navitorā¢ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis
(NYSE:ABT) Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from...
Related Questions
How will the CE mark expansion for Navitorā¢ affect Abbott's revenue forecasts and earnings guidance?
What competitive advantage does Navitorā¢ gain in the European TAVI market compared to Medtronic and Edwards Lifesciences?
What are the potential implications for Abbott's share price volatility and analyst sentiment following this regulatory approval?